Inventiva (NASDAQ:IVA) Given New $14.00 Price Target at HC Wainwright

Inventiva (NASDAQ:IVA) had its price objective trimmed by HC Wainwright from $22.00 to $14.00 in a research report released on Thursday morning, Benzinga reports. The brokerage currently has a buy rating on the stock.

Separately, Stifel Nicolaus reduced their target price on shares of Inventiva from $25.00 to $20.00 and set a buy rating on the stock in a report on Thursday. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of Buy and an average price target of $16.50.

Inventiva Price Performance

IVA stock opened at $1.84 on Thursday. The firm has a fifty day moving average price of $2.25 and a 200 day moving average price of $2.96. Inventiva has a fifty-two week low of $1.53 and a fifty-two week high of $4.75.

Hedge Funds Weigh In On Inventiva

A hedge fund recently bought a new stake in Inventiva stock. Virtu Financial LLC bought a new stake in shares of Inventiva S.A. (NASDAQ:IVA) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 10,490 shares of the company’s stock, valued at approximately $38,000. Institutional investors and hedge funds own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.